Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
Investment demonstrates confidence in America’s commitment to science and innovation
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated